Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CYTR $2.47 0.3399 +15.96%
SRNE $5.59 0.6999 +14.31%
CRIS $1.46 0.1400 +10.61%
ADXS $6.12 0.5650 +10.18%
FBIO $2.93 0.2700 +10.15%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NYMX $2.10 -0.0700 -3.23%
APRI $1.14 -0.0295 -2.52%
TCON $6.25 -0.1200 -1.88%
EXEL $4.13 -0.0750 -1.79%
SNSS $0.67 -0.0100 -1.46%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Orlando Health Cancer Center Expands To Full Cancer Treatments

(Orlando Business Journal) Aug 30, 2012 - The Orlando Health’s cancer treatment facility at Health Central is now offering full medical oncology, chemotherapy and infusion, Orlando Health announced Aug. 30.
read article 



18,500 Patients Receive Treatment Through Cancer Drugs Fund

(Cancer Research UK/Press Association) Aug 30, 2012 - A temporary government scheme has allowed thousands of cancer patients in England to receive drugs that are not routinely available on the NHS, according to new figures released today.
read press release 



Quest Diagnostics Launches Molecular Cervical Cancer Test Based on National Institutes of Health's TERC Gene Marker

(Morningstar) Aug 30, 2012 - Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer.
read article 



Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta

(TheStreet) Aug 31, 2012 – Here's the last Biotech Stock Mailbag of the summer…let's dissect Rexahn's press release this week announcing results from a phase II study of the company's experimental drug Archexin in pancreatic cancer.
read article 



VLST Scoops Up Antibody for Cancer From Pfizer

(Xconomy Seattle) Aug 31, 2012 - Biopharmaceutical companies, sooner or later, must get drug candidates moving through clinical trials where most of the value gets created for investors.
read article 



New Research Uncovers Diverse Metabolic Roles for PML Tumor Suppressor Gene

(BIDMC) Aug 30, 2012 - Two papers led by scientific teams from the Cancer Genetics Program at Beth Israel Deaconess Medical Center (BIDMC) shed new light on the genetic mechanisms underlying cellular energy and metabolism and, at the same time, highlight both the challenges and opportunities of genetic approaches to cancer treatment.
read press release 



Cancer Gene Family Member Functions Key to Cell Adhesion and Migration

(UNC Lineberger CCC) Aug 30, 2012 - The WTX gene is mutated in approximately 30 percent of Wilms tumors, a pediatric kidney cancer. Like many genes, WTX is part of a family. In this case, WTX has two related siblings, FAM123A and FAM123C.
read article 



Breast Cancer Survivors May Face Second Threat: Heart Failure

(NBC News/Vitals blog) Aug 31, 2012 - Women who have survived breast cancer may have to fight another killer down the road -- heart failure, researchers report.
read article 



Breast Cancer Survivors May Face Second Threat: Heart Failure

(NBC News/Vitals blog) Aug 31, 2012 - Women who have survived breast cancer may have to fight another killer down the road -- heart failure, researchers report.
read article 



Novartis to Seek Lung Treatment Launch in Europe, Japan

(Reuters) Aug 30, 2012 - Novartis is to seek approval later this year in Europe and Japan for a new combinaton lung drug to treat so-called smoker's cough after it met expectations in final trials, the Swiss firm said on Thursday.
read article 



Tuberculosis Becoming More Drug-Resistant Worldwide

(ABC News) Aug 30, 2012 - Tuberculosis is growing more resistant to treatment worldwide, according to a study released Wednesday in the journal The Lancet -- a finding that suggests the potentially fatal disease is becoming more difficult and costly to treat.
read article 



Ironwood-Forest Irritable Bowel Therapy Wins FDA Approval

(Bloomberg Businessweek) Aug 30, 2012 - Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. won U.S. regulatory approval of their linaclotide treatment for irritable bowel syndrome with constipation.
read article 



Genmab in Potential $1B Myeloma Drug Deal With J&J

(CNBC/Associated Press) Aug 30, 2012 - Danish drugmaker Genmab A/S said Thursday it could get more than $1 billion from health care giant Johnson & Johnson as the companies develop an experimental cancer treatment.
read article 



Exelixis Says FDA Drops Panel Talks on Thyroid Cancer Drug

(Reuters) Aug 29, 2012 - Exelixis Inc said U.S. regulators have dropped an advisory panel discussion on the marketing application for its experimental drug to treat a rare form of thyroid cancer, sending its shares up 6 percent after market.
read article 



Geron Jumps on Analyst View of Cancer Drugs

(Bloomberg Businessweek/Associated Press) Aug 30, 2012 - Shares of Geron Corp. climbed Thursday after a Stifel Nicolaus analyst said the company should report a series of positive results from clinical trials of two cancer drugs over the coming months.
read article 



Ohio State Leads International Pancreatic Cancer Treatment Development Effort

(OSUCCC-James) Aug 23, 2012 - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) is leading a an international pancreatic cancer research effort in collaboration with scientific investigators based in Taiwan and Germany to develop new targeted therapies and novel biomarkers for pancreatic cancer.
read press release 



New Pancreatic Cancer Guidelines for Patients Available from NCCN

(NCCN) Aug 29, 2012 - The National Comprehensive Cancer Network® (NCCN®), with the support of the Pancreatic Cancer Action Network, announces the latest addition to the library of NCCN Guidelines for PatientsTM, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
read press release 



Doctors Closing Door on Oncology Drug Reps, Study Says

(Philadelphia Inquirer/Philly Pharma blog) Aug 30, 2012 - Targeted cancer drugs are one of the great hopes for pharmaceutical companies, but a business survey says cancer doctors are limiting visits by sales representatives more than most medical specialists.
read article 



Accretive Health and Cancer Clinics of Excellence to Develop Innovative Program Providing Oncology Care Management

(Yahoo! Finance) Aug 29, 2012 - Accretive Health, Inc., a healthcare technology and services company, and Cancer Clinics of Excellence (CCE), a national network of practice-owned, physician-driven community-based oncology practices, announced today that they have partnered to develop a novel, end-to-end oncology care management offering designed to enable healthcare providers to improve the efficacy and quality of cancer care while simultaneously improving the affordability of the healthcare system.
read article 



Ziopharm Awaits Cancer Drug Data as Wall Street Withholds Judgment

(Xconomy New York) Aug 29, 2012 - Jonathan Lewis, the CEO of New York-based Ziopharm, was stunned earlier this year when he ran across a commercial on YouTube produced by his company’s biggest investor, Fidelity.
read article 



Ariad Says EU Regulator Grants Accelerated Review for Its Cancer Drug Candidate

(Boston.com/Bloomberg) Aug 30, 2012 - Ariad Pharmaceuticals Inc. of Cambridge said the European Union’s drug regulator has granted its request for accelerated assessment of its new cancer medicine, which may lead to a faster approval.
read article (free registration required) 



Bristol-Myers Recalls Vials of Cancer Drug

(CNBC/Associated Press) Aug 30, 2012 - Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose.
read article 



FDA Approves Teva Version of Amgen's Neupogen

(Reuters) Aug 29, 2012 - U.S. drug regulators gave the nod to a Teva Pharmaceutical Industries drug that boosts the production of infection-fighting white blood cells in certain cancer patients receiving chemotherapy.
read article 



Could a Cancer Drug Potentially Prevent Learning Disabilities in Some Kids?

(U-M Health System) Aug 29, 2012 - A drug originally developed to stop cancerous tumors may hold the potential to prevent abnormal brain cell growth and learning disabilities in some children, if they can be diagnosed early enough, a new animal study suggests.
read press release 



Collagen-Seeking Synthetic Protein Could Lead Doctors to Tumor Locations

(Johns Hopkins University) Aug 29, 2012 - Johns Hopkins researchers have created a synthetic protein that, when activated by ultraviolet light, can guide doctors to places within the body where cancer, arthritis and other serious medical disorders can be detected.
read press release